GateHouse Bio (fka sRNAlytics)
An RNA therapeutic company
* Data source: Crunchbase
- Founded
- 2016
- Employees*
- 11-50
- Funding to Date*
- $7.9M
- Website
- gatehousebio.com
"I left my job at Biogen to pursue a vision to turn small RNAs into the next generation biomarkers."
It takes over 4 years and dozens of tests to even diagnose it, and even those are wrong... One in four patients in dementia clinical trials don't even have early-stage dementia, and leads to the 99% drug failure rate.
Gatehouse Bio is a biotech company developing RNA therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect.
More Companies
